Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ACT100 in healthy participants to characterize safety, tolerability, and PK/PD. The study is sponsored by Xiamen Amoytop Biotech Co., L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• ACT100

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Status: NOT_YET_RECRUITING